Valuation: Braxia Scientific Corp.

Market Cap 1.42M 1.01M 907K 837K 757K 96.46M 1.44M 9.99M 3.98M 50.48M 3.8M 3.72M 160M P/E 2022
-0.87x
P/E 2023 -0.43x
Enterprise Value 161K 115K 103K 95.29K 86.23K 10.98M 164K 1.14M 454K 5.75M 433K 424K 18.2M EV / Sales 2022
2,322,657x
EV / Sales 2023 2,832,851x
Free-Float
100%
Yield 2022 *
-
Yield 2023 -
3 years 0
Extreme 0.005
0.02
5 years 0
Extreme 0.005
0.19
10 years 0
Extreme 0.005
2.4
Manager TitleAgeSince
Director of Finance/CFO - 2023-11-27
Chief Tech/Sci/R&D Officer - 2021-05-27
Corporate Officer/Principal - 2018-06-30
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap. Importance
7/16/21 Other

Chief Financial Officer

0 0%
7/16/21 Option

Chief Financial Officer

1,800,000 1.0153%
7/15/21 Other

Chief Financial Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-66.67% 1.01M
+0.42%-4.39%+12.07%+36.26% 116B
+3.21%+2.30%+2.07%+112.21% 104B
+2.73%+8.63%+126.13%+1,039.57% 62.85B
+2.20%+11.59%+48.37%+85.04% 29.89B
+1.05%+3.74%-7.04%+92.23% 29.55B
+2.97%+3.96%+44.71%+98.09% 27.83B
+0.77%-0.02%+29.37%+409.36% 21.79B
-0.72%+5.53%-18.98%-7.55% 20.66B
0.00%-0.63%-4.27%+31.71% 17.09B
Average +1.26%+2.78%+23.24%+183.02% 42.87B
Weighted average by Cap. +1.71%+2.03%+28.44%+229.63%

Financials

2022 2023
Net sales 1.49 1.06 0.95 0.88 0.8 101.28 1.51 10.49 4.18 53 3.99 3.91 167.88 1.88 1.35 1.21 1.11 1.01 128.32 1.91 13.28 5.3 67.15 5.06 4.95 212.7
Net income -12.13M -8.68M -7.77M -7.17M -6.49M -826M -12.33M -85.55M -34.13M -432M -32.57M -31.87M -1.37B -13.14M -9.4M -8.42M -7.77M -7.03M -895M -13.35M -92.65M -36.96M -468M -35.27M -34.52M -1.48B
Net Debt -8.46M -6.05M -5.42M -5M -4.52M -576M -8.6M -59.65M -23.8M -302M -22.71M -22.22M -955M -1.26M -898K -804K -742K -671K -85.48M -1.28M -8.85M -3.53M -44.74M -3.37M -3.3M -142M
Logo Braxia Scientific Corp.
Braxia Scientific Corp. is a Canada-based medical research and telemedicine company with a clinic that provide ketamine treatments for persons with depression and related disorders. Through its medical solutions, it intends to reduce the illness burden of brain-based disorders, such as major depressive disorder, among others. The Company is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. It seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. The Company has clinic operations in the Canadian cities of Mississauga, Kitchener-Waterloo, Ottawa and Montreal. Its subsidiary, Braxia Health, is engaged in offering rapid onset treatments to aid those suffering from several treatment-resistant conditions, such as depression and bipolar disorder.
Employees
-
  1. Stock Market
  2. Stocks
  3. BRAX Stock